m+Medelevator.RU
← Поиск публикаций
International immunopharmacology · 2026

Ginsenoside Rg1/Rb1 relieves periodontitis via inhibiting IKBKG -mediated NF-κB pathway to enhance COL1A1 expression.

СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Liu Li, Li Jiahui, Bai Xiaoping, Ma Lijuan, Guo Chunxia, Niu Lei, Sun Shirun, Ma Xiaoxue, Zhao Wei

Аннотация

BACKGROUND: Periodontitis is a chronic inflammatory disease driven by microbial dysbiosis, and effective pharmacological strategies remain limited. This study evaluated whether combined ginsenoside Rg1/Rb1 protects against periodontitis and whether this protection involves IKBKG-dependent NF-κB regulation with restoration of COL1A1.

METHODS: Periodontitis was induced in rats by steel-wire ligation plus Porphyromonas gingivalis lipopolysaccharide (Pg-LPS) challenge, followed by local gingival administration of Rg1/Rb1. In parallel, Pg-LPS-stimulated human periodontal ligament stem cells (hPDLSCs) were used to model inflammation-impaired periodontal ligament stem cells, and IKBKG was knocked down to test causality.

RESULTS: In vivo, Rg1/Rb1 dose-dependently attenuated periodontal inflammation and alveolar bone resorption, accompanied by reduced IL-6 and TNF-α levels, preservation of bone volume, up-regulation of IKBKG and COL1A1, and suppression of NF-κB activation. In vitro, Rg1/Rb1 preserved hPDLSC viability, restored osteogenic differentiation-related proteins (ALP, OCN, RUNX2, and COL1A1), and reduced inflammatory cytokine production. IKBKG knockdown abolished these protective effects, indicating that Rg1/Rb1 acts through IKBKG-dependent control of NF-κB signaling.

CONCLUSION: Combined ginsenoside Rg1/Rb1 alleviates periodontitis by coupling anti-inflammatory activity to restoration of COL1A1 and osteogenic differentiation-related programs through IKBKG-dependent NF-κB regulation, supporting its potential as a therapeutic strategy for periodontitis.

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты